Reimbursement Listing in 2018-2019

• Chuikyo OKs Listing of Astellas’ AML Med, Lilly’s Verzenio and More on Nov. 20
  November 14, 2018

• Maviret Faces 25% Price Slash in Quarterly Review
  November 14, 2018

• Despite Being 4th in ALK Class, Lorbrena Qualifies for PMP as It Gets 5% Pricing Premium
  November 14, 2018

• Novo Skips August Listing of Ozempic after Pricing Talks Fail
  August 23, 2018

• Chuikyo OKs Pricing of Entyvio, Imfinzi, Gazyva and More; Listing on Aug. 29
  August 22, 2018

• Just Months after Big Re-Pricing, Opdivo Faces 37.5% Price Slash on Dose Change
  August 22, 2018

• Chuikyo Rep Frowns on Low Manufacturing Cost Disclosure, Says New Rule Might Need Revisiting
  May 17, 2018

• Chuikyo Reps Chide Delay in Parmodia Listing
  May 17, 2018

• Pricing OK’ed for Hemlibra, Parmodia; Prevymis 1st in 3 Years to Get At-Launch Premium for Innovation
  May 17, 2018

• Chuikyo Payer Rep Questions New Premium System for Cost-Based Pricing Method
  April 12, 2018

• Pricing OK’ed for Dupixent, Tecentriq, Lynparza, and More; Parmodia Skips Listing Yet Again
  April 11, 2018

ページ